Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin - Immune System Regulation

Drug Profile

Triptorelin - Immune System Regulation

Alternative Names: ISR-48; ISR048; Triptorelin acetate depot - Immune System Regulation

Latest Information Update: 28 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune System Regulation
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections
  • No development reported Herpes simplex virus infections

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in Sweden
  • 30 Mar 2021 Triptorelin is still in phase-II clinical trials in HIV-1 infections (Treatment-naive) in South Africa (IM) (Immune System Regulation pipeline, March 2021)
  • 30 Mar 2021 Triptorelin is still in phase-II clinical trials in HIV-1 infections (Treatment-naive) in Sweden (IM) (Immune System Regulation pipeline, March 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top